Acadia Pharmaceuticals Archives - San Diego Biotechnology Connection

Acadia Pharmaceuticals focusing on Nurr1-active drug to treat Parkinson's disease, San Diego Biotechnology Connection

Fox Foundation awards $322k for Parkinson’s Pharmaceuticals to Acadia

March 27, 2012 no comments

By Rex Graham Acadia Pharmaceuticals Inc., a San Diego-based biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous sy Read More

Stock Daily Change

ADMP	0.68		0.00
AEMD	0.10		0.00
AHRO	0.70		0.00
AIMM	0.0035		0.00
AMGN	105.62		0.00
ANX	0.733		0.00
APRI	2.65		0.00
ARNA	8.06		0.00
ATEC	1.94		0.00
AVNR	3.40		0.00
AVTO	0.005		0.00
AXMP	0.015		0.00
AXRX	0.16		0.00
CADX	6.97		0.00
CELG	123.64		0.00
CORX	0.05		0.00
CXM	0.0949		0.00
CYTX	2.57		0.00
CYTR	2.34		0.00
DRAD	2.40		0.00
DXCM	20.27		0.00
ENTB	0.0021		0.00
FOLD	3.42		0.00
HALO	7.45		0.00
HRBR	0.19		0.00
IAGXQ	0.179		0.00
ILMN	71.08		0.00
IMBI	0.028		0.00
ISCO	0.29		0.00
ISIS	20.64		0.00
IVRO	0.0185		0.00
LGND	27.95		0.00
LIFE	73.94		0.00
LJPC	0.077		0.00
LPTN	4.94		0.00
MCK	117.28		0.00
MEDS	1.10		0.00
MEIP	8.32		0.00
MLPH	0.018		0.00
MNKD	6.85		0.00
MNOV	3.17		0.00
MRIC	1.20		0.00
NAII	4.60		0.00
NBIX	12.71		0.00
NRDCQ	0.0001		0.00
NUXP	0.0016		0.00
ONCS	0.309		0.00
OPTR	14.67		0.00
OREX	6.48		0.00
PCRX	29.73		0.00
PFE	29.11		0.00
QDEL	22.10		0.00
RHHBY	65.56		0.00
RMD	50.02		0.00
SNTS	22.93		0.00
SQNM	4.08		0.00
TSRX	7.90		0.00
VOLC	17.00		0.00
VRX	74.67		0.00
VRNM	2.23		0.00
VVUS	14.50		0.00
ZGNX	1.57		0.00

2013-05-23 15:49

@SDBiotech

Trius Therapeutics: New, Positive Dimension For Investment Outlook http://t.co/rcVXC57kkN $CBST $TEVA $TSRX
10 days ago
Retweet
@ilus_art Gorgeous way to celebrate art, biology and cells.
19 days ago
Retweet
Trius Therapeutics releases persuasive safety study of potent new antibiotic against MRSA #superbug. http://t.co/uRBiPHj14U
25 days ago
Retweet
Halozyme initiates Phase 2 trial of drug to treat stage 4 pancreatic cancer. http://t.co/U9cjxGbtIL
31 days ago
Retweet
Illumina’s stronger than expected revenue up 21% sends shares up 13%. http://t.co/qviU0MYLQ3
31 days ago
Retweet
Trius presenting clinical-trial results Apr. 27 http://t.co/MCFeBYi57w on tedizolid, a potent MRSA antibiotic. http://t.co/myB421ZD2n
31 days ago
Retweet
After Thermo Fisher Scientific buys Life Technologies, sequencing leader Illumina may finally sell. http://t.co/F92ndBP0z2
39 days ago
Retweet
http://t.co/y8xbsAQ4q8
63 days ago
Retweet
FDA reviewing diabetes drugs causing pancreas precancers. Affected: Lilly, Merck, Novo Nordisk, Bristol-Myers. http://t.co/2dPyRAYLsc
70 days ago
Retweet

San Diego Biotechnology Connection

The share price of Trius Therapeutics (TSRX) has rebounded almost fully from its 10 percent dip in the New Year that was triggered by its public offering of 7 million shares; however, uncertainty about the company’s lead investigational drug is a lingering February hangover. Small investors face a dilemma: should they dump their diluted shares, double down? Our story explains why we recommend doubling down: http://sandiegobiotechnology.com/topics/5733/trius-dump-or-double-down-on-maker-of-mrsa-antibiotic/
102 days ago
A Glaxo Smith Kline genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc., and San Diego-based Vical, Inc., offer new hope. http://sandiegobiotechnology.com/topics/5600/glaxo-genital-herpes-vaccine-flops-but-genocea-a-buy-in-vaccine-space/
161 days ago
The Dow was off 1.82 percent, down 243.36 points to 13,102.53 at the close of trading Oct. 23 amid disappointing earnings reports. But 11 publicly traded San Diego biotechs gained for the day. https://sandiegobiotechnology.com/topics/5443/eleven-san-diego-biotech-stocks-rise-amid-tuesday-plunge-in-dow/
212 days ago
Millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD), which identifies their healthiest embryos at in vitro fertilization (IVF) clinics. These blastocysts, embryos with 50-150 cells, are at a very favorable stage for implantation and pregnancy. The inner cell mass will give rise to the actual cells of the fetus. The other cells that surround and protect the inner cell mass give rise to the fetal part of the placenta. Photo: Robert Shabanowitz, Gesinger Medical Center
214 days ago
It’s more than a 5-hour energy jolt. Cardium Therapeutics’ purchase of To Go Brands and its nationwide marketing network will give the San Diego biotech company a permanent sales boost for its own nutritional supplements -- and a larger piece of the $30 billion supplements market. https://sandiegobiotechnology.com/topics/5393/cardium-boosts-energy-supplement-sales-with-national-marketing-muscle/
234 days ago